10-QPeriod: Q3 FY1993

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Sep 30, 1993

Filed July 8, 1994For Securities:JNJ

Summary

This 10-Q filing for Johnson & Johnson (JNJ) covers the period ending September 29, 1993. While the filing itself is from July 1994, the financial data pertains to the third quarter of 1993. Investors would look to this report for an update on the company's financial performance and operational status during that period. Key areas of interest typically include sales, earnings, segment performance, and any significant disclosures or events impacting the business. Given the historical nature of this filing, a direct analysis of financial statements is not possible with the provided text. However, in a typical 10-Q, investors would be seeking insights into the company's ability to generate revenue, manage costs, and maintain profitability across its diverse business segments. Any commentary on market conditions, competitive landscape, or strategic initiatives would also be crucial for understanding the company's trajectory at that time.

Key Highlights

  • 1Filing Date: July 7, 1994
  • 2Period Ending: September 29, 1993
  • 3Company: Johnson & Johnson (JNJ)
  • 4Document Type: Quarterly Report (10-Q)
  • 5Content Focus: Financial performance and operational updates for the third quarter of 1993.
  • 6Historical Filing: This report provides a snapshot of JNJ's business from over 30 years ago.
  • 7Investor Information: Essential for understanding historical financial trends and business context of JNJ in 1993.

Frequently Asked Questions

The primary purpose of this 10-Q filing is to provide investors and the public with a quarterly update on Johnson & Johnson's financial performance, operational results, and any significant events or changes that occurred during the period ending September 29, 1993.

Although the specific financial statements are not provided in the text, a typical 10-Q filing would include unaudited financial statements such as the balance sheet, income statement, and cash flow statement for the quarter and year-to-date periods. It would also contain management's discussion and analysis (MD&A) of financial condition and results of operations, and disclosures on legal proceedings or other material events.

This filing is a historical document. The SEC requires companies to file financial reports periodically. The period ending date (September 29, 1993) indicates the cutoff for the financial data presented. The filing date (July 7, 1994) is when the company officially submitted the report to the SEC, which is a routine process following the end of a reporting period, allowing time for preparation and review of the financial statements.

While not detailed in the provided text, Johnson & Johnson historically operates across three major segments: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health Products. Investors would typically examine the performance of each of these segments in the 10-Q to understand the company's diversified revenue streams and growth drivers.